Key Highlights
- UnitedHealth (NYSE:UNH) dropped 10.21% on November 18, after a 5.42% fall on November 17, leaving the two-day loss near 15%.
- The stock was the heaviest weight on the Dow, which lost 561.25 points, or 1.11%, to close at 50,198.17.
- CMS has proposed projecting Medicare Advantage audit errors onto whole plan contracts, beginning with payments made in 2018.
- The agency puts expected recoveries at about USD 90.2 billion across 2027 to 2036, and comments close on January 19, 2027.
The Second Session of Heavy Selling
The Wednesday decline was UnitedHealth's second sharp fall in two sessions, after a 5.42% slide on Tuesday, so the pair of days removed close to 15% of the share price. Because the Dow is price weighted and UnitedHealth trades at a high share price, its move accounted for a large share of the index's 561.25 point decline. The Dow finished at 50,198.17, while the S&P 500 retreated only 0.23% and the Nasdaq Composite advanced 0.42%, which suggests the damage was concentrated in health care. That sector shed 2.20%, second only to energy among the 11 sectors in weakness. Other insurers were pulled down too; Humana was off 12.98%, while Elevance Health and Centene slid 7.63% and 7.03%, and CVS Health gave up 5.20%. Losses were heaviest where Medicare Advantage exposure is greatest, pointing to a specific financial concern instead of a sector-wide rotation. No large insurer was spared, and the slide carried the stock to some of its lowest prices in several years, which is unusual for a Business traditionally regarded as defensive.
The CMS Proposal Explained
On November 16, the Centers for Medicare and Medicaid Services published a proposal to claw back more improper payments to Medicare Advantage plans. Under it, error rates observed in a sample of enrollees would be applied to the full plan contract rather than confined to the sampled records, and the method would reach back to payments from 2018. CMS noted that a Texas federal court had struck down comparable provisions in a 2023 rule on procedural grounds, and it now proposes to reinstate them. The agency calculates the measure would bring in roughly USD 90.2 billion between 2027 and 2036. Publication in the Federal Register is set for Thursday, November 19, with public comments due by January 19, 2027. UnitedHealth operates the nation's largest Medicare Advantage book, so it faces two exposures: repayment of past amounts and thinner margins on new business if plans must alter how they document patient conditions. Investors worry that the repayments could be big enough to dent Earnings for several years, although the rule remains only a proposal.
Signals Investors Will Monitor
Because this is a proposal, the final text may differ once comments are weighed. Insurers are likely to contend that extrapolation is unfair without adjusting for mistakes in traditional Medicare, an argument that featured in previous legal fights. Attention will centre on whether UnitedHealth and its rivals say how much of the USD 90.2 billion could land on them and whether they intend to challenge the rule. Industry groups will probably lobby lawmakers too, given how many older Americans depend on Medicare Advantage. Markets face extra pressure: the 10-year Treasury Yield sits close to 5.07%, and the Fed minutes indicated that nearly every official expects further rate increases. Income investors who own UnitedHealth for its Dividend will want to know whether the payout and buyback programmes survive if the rule is finalised. Until more clarity arrives, the shares are likely to respond to headlines about the rule and any Washington reaction, and a softer final version would probably draw buyers back quickly.
Where Things Stand
UnitedHealth has shed about 15% across two sessions as CMS proposed broader Medicare Advantage audits. The comment deadline of January 19, 2027 and the company's responses will determine what happens next.






Please wait processing your request...